Two separate periods of Intensive research, with a 25-year hiatus after the advent of the sulfonamides, have resulted in two good, but imperfect, anti meningococcal vaccines—against serogroups A and C. Neither is recommended for routine use. but both have been effective in halting epidemics. Lack of an effective group B immunogen remains the major obstacle to the control of meningococcal disease.